TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3543705
Drug: Oral colistin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral colistin
Study: 3543705
Drug: Prophylactic use
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic use of antibiotics
Study: 21122063
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of pioglitazone 15mg/metformin 850mg twice daily (bid)
Study: 21122063
Drug: Metformin 850mg
Normalized name: METFORMIN 850MG/PIOGLITAZONE 15MG TAB
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 850mg bid
Study: 15301640
Drug: Cognitive‐behavioral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive‐behavioral treatment (CBT)
Study: 9052519
Drug: 4-aminosalicylic acid
Normalized name: 4-aminosalicylic acid
DrugBank: Aminosalicylic acid (DB00233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-aminosalicylic acid (4-ASA) 6 g per day for 6 weeks
Study: 19112513
Drug: 15 microg
Normalized name: Tafluprost 15 microgram/mL eye drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 microg HA with aluminium hydroxide adjuvant (half dose)
Study: 19112513
Drug: 3.8 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.8 microg HA without adjuvant (half dose)
Study: 10342944
Drug: Oral cefpodoxime
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cefpodoxime
Study: 10342944
Drug: Amoxicillin +
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin + clavulanate
Study: 11322266
Drug: Didanosine once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine once daily (270 mg/m2/day)
Study: 11322266
Drug: Didanosine twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine twice daily (270 mg/m2/day)
Study: 11322266
Drug: Didanosine twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine twice daily
Study: 1556423
Drug: Oxygen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen (2 L by nasal prongs)
Study: 24635120
Drug: VR graded
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR graded exposure therapy (VR‐GET)
Study: 21083769
Drug: 1.8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g/day of Lippia citriodora extracts (PLX(®) -group)
Study: 16858168
Drug: Glomerular filtration
Normalized name: SNAIL SECRETION FILTRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glomerular filtration rate in mL/min/1.73 m(2)
Study: 12963590
Drug: Osteopathic manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic manipulative treatment plus routine pediatric care
Study: 10394475
Drug: Olanzapine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (25 mg/day for 8 weeks)
Study: 10394475
Drug: Clozapine (693
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (693 mg/day for 8 weeks)
Study: 6147549
Drug: Prednisolone only
Normalized name: Prednisolone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone only (0.3 mg/kg daily, increased weekly)
Study: 31449915
Drug: TLR3 agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: TLR3 agonist
Study: 31449915
Drug: Cytokine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine treatment
Study: 29553081
Drug: Commercial anesthetic
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial anesthetic gels
Study: 24285122
Drug: CapsoCam capsule
Normalized name: Capsicum
DrugBank: Capsicum (DB10897)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CapsoCam capsule
Study: 19412831
Drug: 114 g
Normalized name: Hydrocortisone 1.14 g in 114 g TOPICAL LOTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 114 g SBC
Study: 19412831
Drug: 60 g
Normalized name: aspirin 60 Grains
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 g SBC with 144 g cooked paddy‐rice
Study: 19412831
Drug: 144 g
Normalized name: TITANIUM DIOXIDE 0.018 g in 180 mL / HYPOCHLOROUS ACID 0.0144 g in 180 mL TOPICAL GEL [Beklyn Absolute Purifying Hand Gel Refreshing Aloe 180ml]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 144 g cooked paddy‐rice
Study: 17618137
Drug: Tizanidine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tizanidine (4 mg in the evenings for the first 2 postoperative days)
Study: 17618137
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antibiotic and anti-inflammatory medications only)
Study: 15321438
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg (group O4, n = 23)
Study: 15321438
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg (group O8, n = 25)
Study: 12243809
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin, vinblastine, and mitomycin-C (later dropped) followed by surgery
Study: 12243809
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin, vinblastine (without mitomycin-C) followed by radiation therapy (RT)
Study: 12243809
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by surgery or RT
Study: 12243809
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy only
Study: 2550402
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg MK-906
Study: 2550402
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg MK-906
Study: 25475413
Drug: THC/CBD oromucosal
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC/CBD oromucosal spray
Study: 21956711
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with pioglitazone (45 mg/day) and exenatide (10 μg twice daily) for 12 months
Study: 19930832
Drug: BG >or=
Approvals — FDA: no, EMA: no, PMDA: no
Description: BG >or= 80 mg/dl
Study: 19930832
Drug: TV <or=
Approvals — FDA: no, EMA: no, PMDA: no
Description: TV <or= 6 ml/kg
Study: 19930832
Drug: Analgesia monitoring,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Analgesia monitoring, sedation monitoring, MAP >or= 60 mmHg, BG >or= 80 mg/dl and <or= 130 mg/dl, PIP <or= 35 cmH(2)O, TV <or= 6 ml/kg
Study: 12502992
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural infusion of local anesthetic and opioid (n = 34)
Study: 12502992
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care analgesic regimen (intramuscular meperidine, n = 34)
Study: 10921442
Drug: No preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No preparation (control group)
Study: 8699777
Drug: Placebo (+500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (+500 mg of metamizol)
Study: 31277102
Drug: Xiao'er Feire
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xiao'er Feire Kechuan Oral Solution
Study: 31277102
Drug: Macrolide antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Macrolide antibiotics (erythromycin and azithromycin)
Study: 26330437
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 1000 mg plus Vitamin E 1000 IU
Study: 23676961
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of epidural and general anesthesia (Group C)
Study: 16606934
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (daily or biweekly injections)
Study: 11246616
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 mg orally) followed by octreotide (100 microg subcutaneously)
Study: 11246616
Drug: Octreotide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (100 microg subcutaneously) in patients receiving beta-blockers
Study: 9101010
Drug: Metformin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin with insulin
Study: 8287573
Drug: Oestrogen replacement
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen replacement therapy (oestradiol valerate 2 mg/day)
Study: 3449561
Drug: Oral solution
Normalized name: Oral Solution
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral solution of vancomycin
Study: 3449561
Drug: Semi-solid matrix
Normalized name: Matrix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semi-solid matrix capsules of vancomycin
Study: 29076376
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate 100 mg and metformin 500 mg
Study: 24903122
Drug: Decision Aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision Aid (DA) for skin cancer treatment options and value clarification activity
Study: 16816509
Drug: Plasma derived
Normalized name: c1-inhibitor, plasma derived
DrugBank: Human C1-esterase inhibitor (DB06404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma derived hepatitis B vaccine (pre‐S and S antigens)
Study: 16816509
Drug: Recombinant hepatitis
Normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant hepatitis B vaccine (S antigen only)
Study: 14627860
Drug: 644 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 644 mg/d DT56a
Study: 14627860
Drug: 344 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 344 mg/d DT56a supplemented with calcium
Study: 9111487
Drug: Specific immunotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific immunotherapy (SIT) with standardized allergen extracts
Study: 1587966
Drug: IV omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV omeprazole 40 mg over 2.5 min
Study: 1587966
Drug: IV omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV omeprazole 80 mg over 5 min
Study: 2941404
Drug: Teicoplanin 200
Normalized name: Teicoplanin 200 mg powder for solution for injection vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin 200 mg intramuscularly
Study: 2941404
Drug: Amoxycillin 3
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 3 g orally
Study: 30326952
Drug: Monthly malaria
Normalized name: Plasmodium malariae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly malaria prophylaxis (MMP) with dihydroartemisinin-piperaquine and weekly primaquine for 12 weeks
Study: 30326952
Drug: Focused screening
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused screening and treating (FSAT) following current Cambodian national treatment guidelines
Study: 27685606
Drug: Neutralizing IL‐25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutralizing IL‐25 antibody
Study: 22072378
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg Astaxanthin (AXT) per day for 4 weeks
Study: 7866682
Drug: CATEGO syndromes
Normalized name: Syndros
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CATEGO syndromes SD and OD (biological features of depression)
Study: 27495295
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss intervention (16 weekly group sessions or 5 group sessions and 10 phone calls) (Phase II)
Study: 10542973
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate dry powder inhaler (MF DPI) 100 mcg b.i.d.
Study: 10542973
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate dry powder inhaler (MF DPI) 200 mcg b.i.d.
Study: 10542973
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate dry powder inhaler (MF DPI) 400 mcg b.i.d.
Study: 10542973
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) 168 mcg b.i.d.
Study: 28300506
Drug: SOC +
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SOC + Cel (Celecoxib 400 mg twice a day for 1 year)
Study: 28300506
Drug: SOC +
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SOC + ZA + Cel (Zoledronic acid 4 mg for six 3-weekly cycles, then 4-weekly for 2 years, plus Celecoxib 400 mg twice a day for 1 year)
Study: 28300506
Drug: SOC (Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC (Standard of care hormone therapy)
Study: 25455832
Drug: Manual and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual and manipulative therapy (MMT) alone
Study: 15337407
Drug: 10-day melarsoprol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day melarsoprol treatment
Study: 15337407
Drug: Alternative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative treatment (10-day melarsoprol)
Study: 11177478
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied 3 times/week
Study: 11177478
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream applied once per day
Study: 14753231
Drug: triazolam (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: triazolam (0.25 mg)
Study: 9342777
Drug: capsule chosen
Normalized name: LANCET,CHOSEN DEVICE
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule chosen (either placebo or triazolam)
Study: 7933683
Drug: 201Tl reinjection
Normalized name: Thallium (201Tl) chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 201Tl reinjection SPECT with sublingual nitroglycerin (NTG)
Study: 7933683
Drug: 201Tl reinjection
Normalized name: Thallium (201Tl) chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 201Tl reinjection SPECT without sublingual nitroglycerin (NTG)
Study: 20943066
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with monomeric allergoid (Lais, Lofarma) at three different maintenance doses
Study: 18548957
Drug: Mandibular dentures
Normalized name: ALCOHOL,DENATURED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular dentures retained by 1 or 2 implants
Study: 6857178
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) administration
Study: 17208410
Drug: VPA syrup
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA syrup (250mg)
Study: 17208410
Drug: VPA capsule
Normalized name: VPA
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VPA capsule (250mg)
Study: 17208410
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium sprinkle capsule (250mg)
Study: 17208410
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium enteric-coated delayed-release tablet (250mg)
Study: 17208410
Drug: Divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Divalproex sodium extended-release (divalproex-ER) tablet (250mg)
Study: 2903874
Drug: Intravenous streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous streptokinase (1.5 million units over 1 hour)
Study: 2903874
Drug: Oral aspirin
Normalized name: aspirin Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral aspirin (160 mg/day for 1 month)
Study: 2903874
Drug: Both streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both streptokinase and aspirin
Study: 2899772
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of streptokinase and aspirin
Study: 631642
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion at 0.12 microgram/min
Study: 631642
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion at 0.25 microgram/min
Study: 631642
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion at 4 microgram/min
Study: 631642
Drug: Adrenaline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adrenaline infusion (various doses)
Study: 28844118
Drug: MDCO-216 (5-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDCO-216 (5-40 mg/kg)
Study: 23644901
Drug: No CPAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: No CPAP therapy (Control)
Study: 19470987
Drug: Optimized antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized antidepressant therapy followed by a pain self-management program (12 weeks of therapy + 6 sessions of self-management over 12 weeks + 6 months continuation)
Study: 19470987
Drug: Optimized antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized antidepressant therapy followed by a pain self-management program
Study: 15502599
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 to 60 mg/day
Study: 27255431
Drug: GL +
Normalized name: GL-2045
DrugBank: GL-2045 (DB16971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GL + sita (sitagliptin + insulin glargine)
Study: 27255431
Drug: NOV (premixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOV (premixed insulin aspart 30)
Study: 25448109
Drug: Full-dose IPV
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose IPV intramuscularly with needle and syringe
Study: 25448109
Drug: fIPV intradermally
Normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fIPV intradermally administered with one of two new injectors
Study: 25448109
Drug: fIPV administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: fIPV administered with BCG needle
Study: 25448109
Drug: fIPV administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: fIPV administered with a conventional needle-free injector
Study: 21829907
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral group therapy combined with pharmacotherapy
Study: 16909131
Drug: sc‐IL‐2, sc‐IFN‐alpha2a,
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc‐IL‐2, sc‐IFN‐alpha2a, po‐13cRA + inhaled‐IL‐2 (Arm B)
Study: 11302007
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g fish powder
Study: 11302007
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 tablets/day)
Study: 25695403
Drug: MK-7123 50
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-7123 50 mg
Study: 24179013
Drug: Antioxidative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidative therapy (N-acetyl cysteine or MP865)
Study: 21931024
Drug: Early discharge
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early discharge to receive identical antibiotic treatment at home
Study: 21931024
Drug: Continued inpatient
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued inpatient antibiotic therapy
Study: 16879461
Drug: Bupivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 7.5 mg alone
Study: 16879461
Drug: Bupivacaine 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 7.5 mg with 10 microg of fentanyl
Study: 14753029
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg nimesulid bd.
Study: 14753029
Drug: 275 mg
Normalized name: kava root 275 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 275 mg naproxen bd.
Study: 10067689
Drug: EZ-M vaccine
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: EZ-M vaccine
Study: 1975045
Drug: Good adherence
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Good adherence (taking > 75% of prescribed medication)
Study: 7029004
Drug: Glucose/electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose/electrolyte solution
Study: 7029004
Drug: Sugar/salt solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar/salt solution
Study: 30961658
Drug: Sodium benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium benzoate as an adjunctive treatment
Study: 28535237
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (1-time or 2-time injection of 500 mg or 1000 mg according to body weight)
Study: 9588731
Drug: Sulfasalazine (SSZ)
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulfasalazine (SSZ) 50 mg/kg/day (maximum 2,000 mg/day)
Study: 2052798
Drug: hCG vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: hCG vaccine
Study: 29110567
Drug: Ibuprofen 200
Normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg plaster
Study: 15717881
Drug: Lifestyle intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifestyle intervention (L)